Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.51 |
| ▸ | MAPT | P10636 | 7/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | RAB9A | P51151 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.46 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.46 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.46 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.46 |
| ▸ | MERTK | Q12866 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.44 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29729405 | 1.00 | ALDH1A1 (0.51) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL30777879 | 0.85 | ALDH1A1 (0.55) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL703717 | 0.85 | ALDH1A1 (0.55) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL25337966 | 0.83 | APP (0.53) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL1662886 | 0.82 | ALDH1A1 (0.65) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL11199415 | 0.81 | ALDH1A1 (0.54) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL16095273 | 0.81 | MAPT (0.67) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL1897174 | 0.79 | ALDH1A1 (0.57) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL4142866 | 0.79 | ALDH1A1 (0.58) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 | |
| SCHEMBL30686627 | 0.79 | ALDH1A1 (0.58) | ALDH1A1MAPK1MAPTSMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1963344-A1 | ORGANOPHOSPHORIC DERIVATIVES USEFUL AS ANTI-PARASITIC AGENTS | UNIVERSITEIT GENT (BE) | 2008-09-03 | — | — | EP | claimed |
| WO-2007071453-A1 | ORGANOPHOSPHORIC DERIVATIVES USEFUL AS ANTI-PARASITIC AGENTS | UNIVERSITEIT GENT (BE) | 2007-06-28 | — | — | WO | claimed |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | TERNS PHARMACEUTICALS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| CN-111868037-B | Fused cyclic urea derivatives as CRHR2 antagonists | 拉夸里亚创药株式会社 | 2023-10-13 | — | — | CN | disclosed |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | CURIS INC (US) | 2023-06-22 | — | — | US | disclosed |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | Guris, Inc. (US) | 2023-01-24 | — | — | US | disclosed |
| US-20220281849-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | TERNS PHARMACEUTICALS, INC. | 2022-09-08 | — | — | US | disclosed |
| EP-4017875-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | Terns Pharmaceuticals, Inc. (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3774739-B1 | FUSED CYCLIC UREA DERIVATIVES AS CRHR2 ANTAGONIST | RAQUALIA PHARMA INC (JP) | 2022-05-11 | — | — | EP | disclosed |
| WO-2007027527-A2 | ISOINDOLE-IMIDE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2007-03-01 | — | — | US | disclosed |
| CN-1902170-A | 1, 2-di (cyclic) substituted benzene compounds | EISAI R&D MAN CO LTD (JP) | 2007-01-24 | — | — | CN | disclosed |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2006-12-14 | — | — | US | disclosed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| EP-1698620-A1 | BENZENE COMPOUNDS DISUBSTITUTED WITH CYCLIC GROUPS AT THE 1- AND 2-POSITIONS | Eisai Co., Ltd. (JP) | 2006-09-06 | — | — | EP | disclosed |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-6020379-A | Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia | CELL PATHWAYS, INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-3954852-A | Indenylacetic acid compounds | MERCK & CO., INC. (US) | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | CCR10, H1-10, CXCL10 | ALDH1A1 309/4885MAPK1 572/4885MAPT 4459/4885 |
| US-12528791-B2 | Thyroid hormone receptor beta agonist compounds | THRB, THRA, TSHR | ALDH1A1 2577/4885MAPK1 2095/4885MAPT 1208/4885 |
| US-20220281849-A1 | THYROID HORMONE RECEPTOR BETA AGONIST COMPOUNDS | THRB, THRA, TSHR | ALDH1A1 3553/4885MAPK1 3046/4885MAPT 2085/4885 |
| US-20230192687-A1 | FUSED AMINO PYRIDINE AS HSP90 INHIBITORS | HSP90B1, HSP90AB1, HSP90AB2P | ALDH1A1 2720/4885MAPK1 810/4885MAPT 215/4885 |
| US-20070049618-A1 | Isoindole-imide compounds and compositions comprising and methods of using the same | SI, CYP3A5, CYP2D6 | ALDH1A1 1081/4885MAPK1 4566/4885MAPT 553/4885 |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | ALDH1A1 4726/4885MAPK1 2185/4885MAPT 1623/4885 |
| US-20050261291-A1 | 1,2-Di(cyclic)substituted benzene compounds | CCR10, HRH3, HRH2 | ALDH1A1 705/4885MAPK1 690/4885MAPT 2870/4885 |
| US-11560377-B2 | Fused amino pyridine as HSP90 inhibitors | HSP90B1, HSP90AB1, HSP90AB2P | ALDH1A1 2720/4885MAPK1 810/4885MAPT 215/4885 |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | HRH3, CCR10, HRH1 | ALDH1A1 617/4885MAPK1 836/4885MAPT 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.